Neuregulin-1/ErbB signaling: a druggable target for treating heart failure

Current Opinion in Pharmacology

Volumn 9, Issue 2, 2009, Pages 214-219

  Xu, Yabei ^a   Li, Xinyan ^a   Zhou, Mingdong ^a  

^a Zensun Science and Technology Co Ltd   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CARDIAC SPECIFIC MYOSIN LIGHT CHAIN KINASE; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; NEU DIFFERENTIATION FACTOR; RECOMBINANT HUMAN NEU DIFFERENTIATION FACTOR; TRASTUZUMAB; UNCLASSIFIED DRUG;

CALCIUM HOMEOSTASIS; CARDIOTOXICITY; CELL GROWTH; CELL SURVIVAL; CLINICAL TRIAL; DRUG TARGETING; GENE THERAPY; HEART DEVELOPMENT; HEART FAILURE; HEART MUSCLE CELL; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; HEART; HEART FAILURE; HUMANS; ISOENZYMES; MYOCYTES, CARDIAC; NEUREGULIN-1; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 62249192069     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2008.11.004     Document Type: Review

References (57)

1. Britsch S. The neuregulin-I/ErbB signaling system in development and disease. Adv Anat Embryol Cell Biol 190 (2007) 1-65
2. Schade B., Lam S.H., Cernea D., Sanguin-Gendreau V., Cardiff R.D., Jung B.L., Hallett M., and Muller W.J. Distinct ErbB-2 coupled signaling pathways promote mammary tumors with unique pathologic and transcriptional profiles. Cancer Res 67 (2007) 7579-7588
3. Kauraniemi P., and Kallioniemi A. Activation of multiple cancer-associated genes at the ERBB2 amplicon in breast cancer. Endocr Relat Cancer 13 (2006) 39-49
4. Fisahn A., Neddens J., Yan L., and Buonanno A. Neuregulin-1 modulates hippocampal gamma oscillations: implications for schizophrenia. Cereb Cortex 19 (2009) 612-618
5. Jones L.W., Haykowsky M., Peddle C.J., Joy A.A., Pituskin E.N., Tkachuk L.M., Courneya K.S., Slamon D.J., and Mackey J.R. Cardiovascular risk profile of patients with HER2/neu-positive breast cancer treated with anthracycline-taxane-containing adjuvant chemotherapy and/or trastuzumab. Cancer Epidemiol Biomarkers Prev 16 (2007) 1026-1031
6. Pentassuglia L., and Sawyer D.B. The role of Neuregulin-1beta/ErbB signaling in the heart. Exp Cell Res (2008) Epub ahead of print
7. Holmes W.E., Sliwkowski M.X., Akita R.W., Henzel W.J., Lee J., Park J.W., Yansura D., Abadi N., Raab H., Lewis G.D., et al. Identification of heregulin, a specific activator of p185erbB2. Science 256 (1992) 1205-1210. The original identification of NRG-1 in a research for activators of ErbB2.
8. Meyer D., Yamaai T., Garratt A., Riethmacher-Sonnenberg E., Kane D., Theill L.E., and Birchmeier C. Isoform-specific expression and function of neuregulin. Development 124 (1997) 3575-3586
9. Steinthorsdottir V., Stefansson H., Ghosh S., Birgisdottir B., Bjornsdottir S., Fasquel A.C., Olafsson O., Stefansson K., and Gulcher J.R. Multiple novel transcription initiation sites for NRG1. Gene 342 (2004) 97-105
10. Liu X., Hwang H., Cao L., Buckland M., Cunningham A., Chen J., Chien K.R., Graham R.M., and Zhou M. Domain-specific gene disruption reveals critical regulation of neuregulin signaling by its cytoplasmic tail. Proc Natl Acad Sci U S A 95 (1998) 13024-13029
11. Raabe T.D., Deadwyler G., Varga J.W., and Devries G.H. Localization of neuregulin isoforms and erbB receptors in myelinating glial cells. Glia 45 (2004) 197-207
12. Bublil E.M., and Yarden Y. The EGF receptor family: spearheading a merger of signaling and therapeutics. Curr Opin Cell Biol 19 (2007) 124-134. This is a good review that concentrates on recent advances in understanding the mechanism of allosteric activation of ErbB proteins, as well as the current implications of ErbB signaling in diseases.
13. Baliga R.R., Pimental D.R., Zhao Y.Y., Simmons W.W., Marchionni M.A., Sawyer D.B., and Kelly R.A. NRG-1-induced cardiomyocyte hypertrophy. Role of PI-3-kinase, p70(S6K), and MEK-MAPK-RSK. Am J Physiol 277 (1999) H2026-H2037
14. Muthuswamy S.K., Gilman M., and Brugge J.S. Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers. Mol Cell Biol 19 (1999) 6845-6857
15. Kramer R., Bucay N., Kane D.J., Martin L.E., Tarpley J.E., and Theill L.E. Neuregulins with an Ig-like domain are essential for mouse myocardial and neuronal development. Proc Natl Acad Sci U S A 93 (1996) 4833-4838
16. Gassmann M., Casagranda F., Orioli D., Simon H., Lai C., Klein R., and Lemke G. Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature 378 (1995) 390-394
17. Lee K.F., Simon H., Chen H., Bates B., Hung M.C., and Hauser C. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 378 (1995) 394-398
18. Crone S.A., Zhao Y.Y., Fan L., Gu Y., Minamisawa S., Liu Y., Peterson K.L., Chen J., Kahn R., Condorelli G., et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 8 (2002) 459-465
19. Garcia-Rivello H., Taranda J., Said M., Cabeza-Meckert P., Vila-Petroff M., Scaglione J., Ghio S., Chen J., Lai C., Laguens R.P., et al. Dilated cardiomyopathy in Erb-b4-deficient ventricular muscle. Am J Physiol Heart Circ Physiol 289 (2005) H1153-H1160
20. Negro A., Brar B.K., and Lee K.F. Essential roles of Her2/erbB2 in cardiac development and function. Recent Prog Horm Res 59 (2004) 1-12
21. Erickson S.L., O'Shea K.S., Ghaboosi N., Loverro L., Frantz G., Bauer M., Lu L.H., and Moore M.W. ErbB3 is required for normal cerebellar and cardiac development: a comparison with ErbB2-and heregulin-deficient mice. Development 124 (1997) 4999-5011
22. Camenisch T.D., Schroeder J.A., Bradley J., Klewer S.E., and McDonald J.A. Heart-valve mesenchyme formation is dependent on hyaluronan-augmented activation of ErbB2-ErbB3 receptors. Nat Med 8 (2002) 850-855
23. Patel R., and Kos L. Endothelin-1 and Neuregulin-1 convert embryonic cardiomyocytes into cells of the conduction system in the mouse. Dev Dyn 233 (2005) 20-28
24. Rentschler S., Zander J., Meyers K., France D., Levine R., Porter G., Rivkees S.A., Morley G.E., and Fishman G.I. Neuregulin-1 promotes formation of the murine cardiac conduction system. Proc Natl Acad Sci U S A 99 (2002) 10464-10469
25. Milan D.J., Giokas A.C., Serluca F.C., Peterson R.T., and MacRae C.A. Notch1b and neuregulin are required for specification of central cardiac conduction tissue. Development 133 (2006) 1125-1132
26. Ruhparwar A., Er F., Martin U., Radke K., Gruh I., Niehaus M., Karck M., Haverich A., and Hoppe U.C. Enrichment of cardiac pacemaker-like cells: neuregulin-1 and cyclic AMP increase I(f)-current density and connexin 40 mRNA levels in fetal cardiomyocytes. Med Biol Eng Comput 45 (2007) 221-227
27. Lemmens K., Segers V.F., Demolder M., and De Keulenaer G.W. Role of neuregulin-1/ErbB2 signaling in endothelium-cardiomyocyte cross-talk. J Biol Chem 281 (2006) 19469-19477
28. Zhao Y.Y., Sawyer D.R., Baliga R.R., Opel D.J., Han X., Marchionni M.A., and Kelly R.A. Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. J Biol Chem 273 (1998) 10261-10269. A study to examine the role of NRG and their receptors in developing and postnatal myocardium and suggests a continuing role for neuregulins in the myocardial adaptation to physiologic stress or injury.
29. Chien K.R., Knowlton K.U., Zhu H., and Chien S. Regulation of cardiac gene expression during myocardial growth and hypertrophy: molecular studies of an adaptive physiologic response. FASEB J 5 (1991) 3037-3046
30. Liu X., Gu X., Li Z., Li X., Li H., Chang J., Chen P., Jin J., Xi B., Chen D., et al. Neuregulin-1/erbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy. J Am Coll Cardiol 48 (2006) 1438-1447. A study to examine the role of NRG and their receptors in developing and postnatal myocardium and suggests a continuing role for neuregulins in the myocardial adaptation to physiologic stress or injury.
31. Fukazawa R., Miller T.A., Kuramochi Y., Frantz S., Kim Y.D., Marchionni M.A., Kelly R.A., and Sawyer D.B. Neuregulin-1 protects ventricular myocytes from anthracycline-induced apoptosis via erbB4-dependent activation of PI3-kinase/Akt. J Mol Cell Cardiol 35 (2003) 1473-1479
32. Kuramochi Y., Cote G.M., Guo X., Lebrasseur N.K., Cui L., Liao R., and Sawyer D.B. Cardiac endothelial cells regulate reactive oxygen species-induced cardiomyocyte apoptosis through neuregulin-1beta/erbB4 signaling. J Biol Chem 279 (2004) 51141-51147
33. Kubalova Z., Terentyev D., Viatchenko-Karpinski S., Nishijima Y., Gyorke I., Terentyeva R., da Cunha D.N., Sridhar A., Feldman D.S., Hamlin R.L., et al. Abnormal intrastore calcium signaling in chronic heart failure. Proc Natl Acad Sci U S A 102 (2005) 14104-14109
34. Kuramochi Y., Guo X., and Sawyer D.B. Neuregulin activates erbB2-dependent src/FAK signaling and cytoskeletal remodeling in isolated adult rat cardiac myocytes. J Mol Cell Cardiol 41 (2006) 228-235. By experiments on adult rat ventricular myocytes in primary culture, the authors firstly suggested a potential role of NRG-1β/erbB2/Src/FAK signaling in the maintenance and repair of electrical and mechanical coupling in cardiomyocytes.
35. Peng X., Kraus M.S., Wei H., Shen T.L., Pariaut R., Alcaraz A., Ji G., Cheng L., Yang Q., Kotlikoff M.I., et al. Inactivation of focal adhesion kinase in cardiomyocytes promotes eccentric cardiac hypertrophy and fibrosis in mice. J Clin Invest 116 (2006) 217-227
36. Boateng S.Y., Lateef S.S., Mosley W., Hartman T.J., Hanley L., and Russell B. RGD and YIGSR synthetic peptides facilitate cellular adhesion identical to that of laminin and fibronectin but alter the physiology of neonatal cardiac myocytes. Am J Physiol Cell Physiol 288 (2005) C30-C38
37. Mansour H., de Tombe P.P., Samarel A.M., and Russell B. Restoration of resting sarcomere length after uniaxial static strain is regulated by protein kinase Cepsilon and focal adhesion kinase. Circ Res 94 (2004) 642-649
38. Sawyer D.B., Zuppinger C., Miller T.A., Eppenberger H.M., and Suter T.M. Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity. Circulation 105 (2002) 1551-1554
39. Lemmens K., Fransen P., Sys S.U., Brutsaert D.L., and De Keulenaer G.W. Neuregulin-1 induces a negative inotropic effect in cardiac muscle: role of nitric oxide synthase. Circulation 109 (2004) 324-326. This paper shows a direct effect of NRG-1 on contractility of adult cardiac muscle. It also concluded that the inotropic effect of NRG-1 was preserved during adrenergic stimulation and desensitized the myocardium to isoproterenol.
40. Lemmens K., Segers F., and De Keulenaer G.W. Letter regarding article by Okoshi et al, 'neuregulins regulate cardiac parasympathetic activity: muscarinic modulation of {beta}-adrenergic activity in myocytes from mice with neuregulin-1 gene deletion'. Circulation 111 (2005) e175 author reply e175
41. Okoshi K., Nakayama M., Yan X., Okoshi M.P., Schuldt A.J., Marchionni M.A., and Lorell B.H. Neuregulins regulate cardiac parasympathetic activity: muscarinic modulation of beta-adrenergic activity in myocytes from mice with neuregulin-1 gene deletion. Circulation 110 (2004) 713-717
42. Hintsanen M., Elovainio M., Puttonen S., Kivimaki M., Raitakari O.T., Lehtimaki T., Rontu R., Juonala M., Kahonen M., Viikari J., et al. Neuregulin-1 genotype moderates the association between job strain and early atherosclerosis in young men. Ann Behav Med 33 (2007) 148-155
43. Guarneri V., Lenihan D.J., Valero V., Durand J.B., Broglio K., Hess K.R., Michaud L.B., Gonzalez-Angulo A.M., Hortobagyi G.N., and Esteva F.J. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol 24 (2006) 4107-4115
44. Rohrbach S., Niemann B., Silber R.E., and Holtz J. Neuregulin receptors erbB2 and erbB4 in failing human myocardium-depressed expression and attenuated activation. Basic Res Cardiol 100 (2005) 240-249
45. Pentassuglia L., Timolati F., Seifriz F., Abudukadier K., Suter T.M., and Zuppinger C. Inhibition of ErbB2/neuregulin signaling augments paclitaxel-induced cardiotoxicity in adult ventricular myocytes. Exp Cell Res 313 (2007) 1588-1601
46. Go L.O., Moschella M.C., Watras J., Handa K.K., Fyfe B.S., and Marks A.R. Differential regulation of two types of intracellular calcium release channels during end-stage heart failure. J Clin Invest 95 (1995) 888-894
47. Pathak A., del Monte F., Zhao W., Schultz J.E., Lorenz J.N., Bodi I., Weiser D., Hahn H., Carr A.N., Syed F., et al. Enhancement of cardiac function and suppression of heart failure progression by inhibition of protein phosphatase 1. Circ Res 96 (2005) 756-766
48. Jiang M.T., Lokuta A.J., Farrell E.F., Wolff M.R., Haworth R.A., and Valdivia H.H. Abnormal Ca2+ release, but normal ryanodine receptors, in canine and human heart failure. Circ Res 91 (2002) 1015-1022
49. Bassani J.W., Yuan W., and Bers D.M. Fractional SR Ca release is regulated by trigger Ca and SR Ca content in cardiac myocytes. Am J Physiol 268 (1995) C1313-C1319
50. Verboomen H., Wuytack F., De Smedt H., Himpens B., and Casteels R. Functional difference between SERCA2a and SERCA2b Ca2+ pumps and their modulation by phospholamban. Biochem J 286 Pt 2 (1992) 591-595
51. MacDougall L.K., Jones L.R., and Cohen P. Identification of the major protein phosphatases in mammalian cardiac muscle which dephosphorylate phospholamban. Eur J Biochem 196 (1991) 725-734
52. Gupta R.C., Mishra S., Rastogi S., Imai M., Habib O., and Sabbah H.N. Cardiac SR-coupled PP1 activity and expression are increased and inhibitor 1 protein expression is decreased in failing hearts. Am J Physiol Heart Circ Physiol 285 (2003) H2373-H2381
53. El-Armouche A., Rau T., Zolk O., Ditz D., Pamminger T., Zimmermann W.H., Jackel E., Harding S.E., Boknik P., Neumann J., et al. Evidence for protein phosphatase inhibitor-1 playing an amplifier role in beta-adrenergic signaling in cardiac myocytes. FASEB J 17 (2003) 437-439
54. Seguchi O., Takashima S., Yamazaki S., Asakura M., Asano Y., Shintani Y., Wakeno M., Minamino T., Kondo H., Furukawa H., et al. A cardiac myosin light chain kinase regulates sarcomere assembly in the vertebrate heart. J Clin Invest 117 (2007) 2812-2824
55. Chan J.Y., Takeda M., Briggs L.E., Graham M.L., Lu J.T., Horikoshi N., Weinberg E.O., Aoki H., Sato N., Chien K.R., et al. Identification of cardiac-specific myosin light chain kinase. Circ Res 102 (2008) 571-580
56. Rosamond W., Flegal K., Furie K., Go A., Greenlund K., Haase N., Hailpern S.M., Ho M., Howard V., Kissela B., et al. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117 (2008) e25-e146
57. Hajjar R.J., Zsebo K., Deckelbaum L., Thompson C., Rudy J., Yaroshinsky A., Ly H., Kawase Y., Wagner K., Borow K., et al. Design of a phase 1/2 trial of intracoronary administration of AAV1/SERCA2a in patients with heart failure. J Card Fail 14 (2008) 355-367